Zentalis PharmaceuticalsZNTL
Market Cap: $262M
About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
Employees: 168
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
446% more call options, than puts
Call options by funds: $262K | Put options by funds: $48K
40% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 40
17% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 23
3% more funds holding
Funds holding: 139 [Q1] → 143 (+4) [Q2]
13.48% less ownership
Funds ownership: 121.43% [Q1] → 107.95% (-13.48%) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 2 (-2) [Q2]
77% less capital invested
Capital invested by funds: $1.36B [Q1] → $314M (-$1.04B) [Q2]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
Oppenheimer Matthew Biegler 42% 1-year accuracy 11 / 26 met price target | 443%upside $20 | Outperform Reiterated | 16 Sept 2024 |
Wedbush Robert Driscoll 67% 1-year accuracy 47 / 70 met price target | 9%upside $4 | Neutral Upgraded | 12 Aug 2024 |
HC Wainwright & Co. Andrew Fein 45% 1-year accuracy 75 / 165 met price target | 443%upside $20 | Buy Reiterated | 12 Aug 2024 |
UBS Eliana Merle 42% 1-year accuracy 5 / 12 met price target | 36%upside $5 | Neutral Downgraded | 20 Jun 2024 |
Wells Fargo Derek Archila 52% 1-year accuracy 15 / 29 met price target | 145%upside $9 | Equal-Weight Downgraded | 18 Jun 2024 |
Financial journalist opinion
Based on 10 articles about ZNTL published over the past 30 days